Island Pharma Begins Phase 2b Cohort for Dengue
After submitting the SRC's recommendation to the U.S. Food and Drug Administration (FDA) and completing the required 30-day review period, Island Pharmaceuticals has commenced the Phase 2b cohort. The Phase 2a study evaluated the prophylactic (preventive) potential of ISLA-101 against dengue fever, enrolling four participants with a 3:1 randomization of active treatment to placebo. 
Island Pharma Begins Phase 2b Cohort for Dengue